Loading...
Loading...
Stryker Corporation
SYK
announced today a definitive agreement to acquire privately-held Surpass
Medical, Ltd. (Surpass) in an all cash transaction for $100 million and up to
an additional $35 million of milestone payments. Founded in 2005 and
headquartered in Tel Aviv, Israel with manufacturing and R&D in Miramar,
Florida, Surpass is developing and commercializing next-generation flow
diversion stent technology to treat brain aneurysms using a unique mesh design
and delivery system. Surpass' key product, the NeuroEndoGraft family of flow
diverters, is designed to redirect blood flow away from an aneurysm, allowing
a stable clot to be formed within the aneurysm pouch. The NeuroEndoGraft is CE
Marked with a limited launch underway outside the U.S. In addition, the
company will begin enrolling patients in an IDE clinical trial in the fourth
quarter of 2012.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in